glp-1 kidney function agonists in the treatment of chronic disease in type 2 diabetes and obesity CKJ REVIEW GLP-1 receptor agonists

We down regulate the activity of heat producing BAT (brown adipose tissue)

Serious adverse events are rare when dosed appropriately

Are there other health benefits or risks

Phase 1b studies in type 2 diabetes showed dose-dependent HbA1c reductions up to 1.6% and pharmacokinetics supporting once-weekly dosing (t ~6 days)

GLP-1 Market Expands Beyond Obesity Investors increasingly view GLP-1 drugs as a broader metabolic-health platform extending beyond obesity and diabetes into areas such as sleep apnea, kidney disease, cardiovascular risk, liver disease and addiction treatment

12% of adults in America report trying GLP-1 agonists to lose weight or manage diabetes